Tissue Regenix (GB:TRX) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tissue Regenix’s subsidiary, CellRight Technologies, has extended its distribution agreement with Arthrex, Inc. until 2029, ensuring continued access to its innovative orthobiologics for surgical procedures. This extension highlights a strategic partnership aimed at improving patient outcomes through advanced medical technology. Investors may find this development promising as it strengthens Tissue Regenix’s market position in regenerative medicine.
For further insights into GB:TRX stock, check out TipRanks’ Stock Analysis page.